Market Analysis: Smith & Nephew plc (SNN) Sees Price Dip and Increased Trading Volume
Smith & Nephew plc (SNN) is currently priced at $31.51, showing a decrease of 58 cents (-1.81%) from the previous close of $32.09. The trading volume is $249,572, representing a 27.82% increase compared to the average.
The latest quarterly earnings report for Smith & Nephew plc (SNN) was on Monday, March 2nd. The earnings per share stood at 1.18, slightly surpassing the consensus estimate of 1.16.
With a forward dividend yield of 5.93%, Smith & Nephew plc (SNN) distributed 30 cents per share in the most recent quarter, showing a year-over-year increase of 1.6 cents. The trailing twelve months dividend per share is $1.23.
Smith & Nephew plc (SNN) reported a free cash flow of $594.67 million. Noteworthy activities include net acquisitions of $25 million and debt repayment of $100.33 million. The company ended the period with cash amounting to $557 million.
The company generated $3.19 billion in revenue, with a gross profit of $2 billion. Operating income stood at $570.45 million, resulting in a net income of $330.82 million. Earnings per share (EPS) and diluted EPS were 78 cents and 76 cents, respectively.
Key ratios for Smith & Nephew plc (SNN) include a net profit margin of 10.36%, return on assets of 3.27, and a price to earnings ratio of 10.55. The company's price to book ratio is 2.73, indicating its current valuation.
The company holds $557 million in cash and cash equivalents, totaling assets of $10.46 billion. Smith & Nephew plc (SNN) has a total debt of $3.33 billion, resulting in a net debt of $2.77 billion.
This comprehensive financial snapshot of Smith & Nephew plc (SNN) reflects its recent performance and financial health.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.